A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate of watch-and-wait patients was not inferior to that o ...

has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory (“R/R”) follicular lymphoma (“FL”) with EZH2 mutation who have received at ...